Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141206 · ClinicalTrials.gov registry record · Phase 3
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,005
- Enrollment target
NCT00141206: Completed Phase 3 study, sponsored by Pfizer.
NCT00141206 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,005 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00141206, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,005 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.
Interventions
- DRUG varenicline (CP-526,555)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,005 participants |
| Start Date | 2003-05 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
What the finished NCT00141206 record still lists
NCT00141206 is an interventional study that assigns participants to a tested intervention. Its 1,005 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 1 intervention - of which varenicline (CP-526,555) is the first listed.
NCT00141206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00141206 about?
NCT00141206 is a clinical study titled "A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation". The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.
What is the current status of trial NCT00141206?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,005 participants. The study started on 2003-05. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00141206?
The interventions under investigation include: varenicline (CP-526,555) (DRUG).
Who is sponsoring clinical trial NCT00141206?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00141206's enrollment target sits among peer trials
1,005 295th of 2000 higher than 1,706 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04389632 · 1,006 participants · Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia